Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFIRINOX in Gemcitabine-Refractory Pancreatic Cancer
NCT02440958Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by Yonsei University. Started Aug 2015; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02440958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440958.